SUMMARY Clinical, virological, and histological features of hepatitis B virus infection have been examined in 35 children, aged 1 to 11 years, known to be hepatitis B surface antigen (HBsAg) carriers for at least six months when entering the study. Only 10 patients had a history of acute unresolved hepatitis: in the remaining cases the detection of HBsAg had been an occasional finding. Although 77 % of the patients were asymptomatic, all had evidence of hepatic involvement and liver history showed the features of chronic persistent hepatitis in 18 cases and of chronic active hepatitis in 16 cases, with associated cirrhosis in two of them. One patient had only minimal histological changes. A high percentage of children with both chronic persistent and chronic active hepatitis had evidence of active virus replication throughout the observation period. During the follow-up study of one to eight years (mean 3.1 ± 1.7 years), transaminase levels became consistently normal in five patients with chronic persistent hepatitis, and inflammatory infiltrates disappeared in three of them. However, only one of these children cleared HBsAg from serum. Eleven of 16 patients with chronic active hepatitis received immunosuppressive treatment but only one of them achieved a complete and protracted remission, although active viral replication persisted. On the other hand, two of five untreated patients reached complete remission after two and three years of followup respectively and one of them cleared HBsAg three years later. These results would suggest the possibility of a spontaneous complete remission of HBsAg positive chronic active hepatitis in children but also raise doubts about the usefulness of immunosuppressive therapy in such patients. 
When they entered the study all patients were anicteric and only eight were symptomatic, complaining of mild asthenia, anorexia, or vomiting. However, hepatomegaly was detected in all children and was associated with splenomegaly in 10 of them. All patients showed increased transaminase levels, from 1.5 up to 10 times the upper normal limit, while bilirubin levels were within the normal range. Hypergammaglobulinaemia (gammaglobulin exceeding 12 g/l (1.2 g/100 ml) in children aged 1 to 2 years and 15 g/l (15 g/100 ml) in children more than 2 years old) was found in 12 cases, while albumin levels and prothrombin time were always normal in all patients. SMA were transiently detected in three cases, while ANA and AMA were never 
FOLLOW-UP OF CHRONIC ACTIVE H E P A T I TI S P A T I E N T S
Eleven of 16 patients with chronic active hepatitis were started on immunosuppressive treatment with prednisone (2 mg/kg/day) or with a combination of prednisone (1 mg/kg/day) and azathioprine (2 mg/kg/day). When stable improvement of biochemical parameters was achieved-that is, transaminase levels lower than twice the upper (Fig. 1 ) transaminases fluctuated in time in three cases, all HBeAg positive when entering the study, and became normal, after 14 months and two years respectively, in two other cases: one of the latter (case 1) who was HBeAg positive at presentation, seroconverted to anti-HBe, while the other (case 2), who was initially HBeAg/ anti-HBe negative, became anti-HBe positive at the time when liver enzymes had become normal and cleared HBsAg from serum about three years later. In both these cases chronic active hepatitis was of moderate activity at first biopsy. Subsequent liver histology performed after biochemical remission and after the appearance of anti-HBe was characteriseci by substantip changes in parenchymal and mesenchymal lesions. These were represented by a striking reduction or complete disappearance of intralobular inflammation and necrosis, leaving a diffuse hypertrophy of siinusoidal lining cells. The portal tracts appeared to be well delineated from the parenchyma, with minimal cellular inflammation, but prevalent fibrosis. Features of The behaviour of transaminases and of liver histology in the 11 treated patients is shown in Fig. 2 . A sustained normalisation of liver enzymes was obtained after nine to 17 months of treatment in three cases who remained HBeAg positive throughout the observation period. Liver histology at this time was unchanged in one case (case 2) and showed the features of chronic persistent hepatitis in the remaining two children (cases 1 and 3). One of the latter, however, relapsed one year after withdrawal of therapy and liver histology is now again consistent with chronic active hepatitis. In the other eight patients transaminases showed periodical fluctuations despite continued maintenance therapy and liver histology remained unchanged, after one to seven years, in all five children who underwent a second liver biopsy.
Discussion
Of the 35 children with HBsAg positive chronic hepatitis included in this study, only 10 had a history of acute unresolved hepatitis. In all the other cases the detection of HBsAg in serum had been an occasional finding, thus suggesting that, as HBV infection is endemic in Italy, a number of chronic carrier children could remain undetected.
Only one of our children had received blood transfusions and maternoneonatal transmission could be reasonably suspected in three other cases. Thus the source of infection remained undefined in most children, although it can be suggested that, as 57% of mothers had evidence of past HBV infection, vertical transmission of HBV could have occurred in a larger number of e HBeAg/anti- Our follow-up study of children with chronic active hepatitis has shown evidence of the possibility of a spontaneous histological remission with or without final clearance of HBsAg from serum. Indeed, although bioptic sampling errors cannot be excluded, this favourable outcome has been observed in two of five asymptomatic children who did not receive immunosuppressive treatment. On the other hand, only one of 11 treated patients, including also five asymptomatic cases, has so far reached histological remission and no one seroconverted from HBeAg to anti-HBe. In one other patient histological remission was not maintained after withdrawal of therapy and another child achieved only biochemical remission. Therefore these preliminary results of immunosuppressive treatment have not been encouraging in our patients, although no definite conclusions can be drawn because of the small number of patients and the lack of a randomised control group.
Our results are at variance with the findings of Dupuy et al.5 Indeed, these authors reported that 12 out of 12 children with chronic active hepatitis progressed to cirrhosis, and in eight of them the disease became inactive under immunosuppressive treatment, with clearance of HBsAg from serum in six cases. These discrepancies might be due to a different selection of patients; however, they further indicate the need for a controlled trial of immunosuppressive therapy in HBsAg posittive chronic active hepatitis of children, similar to that carried out in HRsAg negative chronic active henatitis,19 to evaluate the real benefit of this treatment and the opportunity of new therapeutic approaches. 
